Tianbo Xu

1.2k total citations
27 papers, 728 citations indexed

About

Tianbo Xu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tianbo Xu has authored 27 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 18 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Tianbo Xu's work include Ferroptosis and cancer prognosis (13 papers), Renal cell carcinoma treatment (9 papers) and Epigenetics and DNA Methylation (5 papers). Tianbo Xu is often cited by papers focused on Ferroptosis and cancer prognosis (13 papers), Renal cell carcinoma treatment (9 papers) and Epigenetics and DNA Methylation (5 papers). Tianbo Xu collaborates with scholars based in China and France. Tianbo Xu's co-authors include Xiaoping Zhang, Hongmei Yang, Hailong Ruan, Di Liu, Ke Chen, Lin Bao, Jingchong Liu, Keshan Wang, Yuenan Liu and Qi Cao and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Cancer Research and Experimental Cell Research.

In The Last Decade

Tianbo Xu

27 papers receiving 722 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tianbo Xu China 19 512 324 305 112 70 27 728
Zhengshuai Song China 17 459 0.9× 253 0.8× 328 1.1× 96 0.9× 64 0.9× 31 689
Lin Bao China 18 620 1.2× 355 1.1× 453 1.5× 147 1.3× 83 1.2× 29 875
Ting Hong China 8 424 0.8× 347 1.1× 350 1.1× 115 1.0× 33 0.5× 14 650
Beatrice Dankworth Germany 5 435 0.8× 244 0.8× 419 1.4× 63 0.6× 33 0.5× 5 641
Wanyong Chen China 12 321 0.6× 192 0.6× 240 0.8× 99 0.9× 38 0.5× 20 540
Maria Quiles del Rey United States 7 373 0.7× 151 0.5× 341 1.1× 108 1.0× 40 0.6× 8 625
Xiaozai Xie China 11 498 1.0× 461 1.4× 382 1.3× 137 1.2× 55 0.8× 15 831
Masaya Yonemori Japan 15 633 1.2× 143 0.4× 494 1.6× 88 0.8× 34 0.5× 30 802
Omar Moussa United States 19 423 0.8× 145 0.4× 203 0.7× 140 1.3× 181 2.6× 25 828

Countries citing papers authored by Tianbo Xu

Since Specialization
Citations

This map shows the geographic impact of Tianbo Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tianbo Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tianbo Xu more than expected).

Fields of papers citing papers by Tianbo Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tianbo Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tianbo Xu. The network helps show where Tianbo Xu may publish in the future.

Co-authorship network of co-authors of Tianbo Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Tianbo Xu. A scholar is included among the top collaborators of Tianbo Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tianbo Xu. Tianbo Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Qi, Su Gao, Zhihao Wei, et al.. (2023). AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis. International Journal of Biological Sciences. 19(4). 1266–1283. 43 indexed citations
2.
Xu, Tianbo, et al.. (2022). A study on the neuroprotective effect of miR-206-3p on Alzheimer’s disease mice by regulating brain-derived neurotrophic factor. Annals of Translational Medicine. 10(2). 85–85. 8 indexed citations
3.
Gao, Su, Hailong Ruan, Jingchong Liu, et al.. (2021). A Novel Ferroptosis-Related Pathway for Regulating Immune Checkpoints in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology. 11. 678694–678694. 7 indexed citations
4.
Xu, Jiaju, Yuenan Liu, Jingchong Liu, et al.. (2021). Low Expression Levels of SLC22A12 Indicates a Poor Prognosis and Progresses Clear Cell Renal Cell Carcinoma. Frontiers in Oncology. 11. 659208–659208. 5 indexed citations
5.
Li, Sen, Yongbiao Cheng, Gong Cheng, et al.. (2021). High SAA1 Expression Predicts Advanced Tumors in Renal Cancer. Frontiers in Oncology. 11. 649761–649761. 20 indexed citations
6.
Shi, Jian, Zhiyong Xiong, Keshan Wang, et al.. (2021). HIF2α promotes tumour growth in clear cell renal cell carcinoma by increasing the expression of NUDT1 to reduce oxidative stress. SHILAP Revista de lepidopterología. 11(11). e592–e592. 10 indexed citations
7.
Wang, Qi, Jiaju Xu, Zhiyong Xiong, et al.. (2021). CENPA promotes clear cell renal cell carcinoma progression and metastasis via Wnt/β-catenin signaling pathway. Journal of Translational Medicine. 19(1). 417–417. 52 indexed citations
8.
Xu, Tianbo, Su Gao, Hailong Ruan, et al.. (2021). METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics. 12. 609174–609174. 19 indexed citations
9.
Xu, Jiaju, Yuenan Liu, Jingchong Liu, et al.. (2020). The Identification of Critical m6A RNA Methylation Regulators as Malignant Prognosis Factors in Prostate Adenocarcinoma. Frontiers in Genetics. 11. 602485–602485. 24 indexed citations
10.
Ruan, Hailong, Zhengshuai Song, Qi Cao, et al.. (2020). IMPDH1/YB-1 Positive Feedback Loop Assembles Cytoophidia and Represents a Therapeutic Target in Metastatic Tumors. Molecular Therapy. 28(5). 1299–1313. 20 indexed citations
11.
Cao, Qi, Zhengshuai Song, Hailong Ruan, et al.. (2019). Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer. Clinical Cancer Research. 26(6). 1516–1528. 45 indexed citations
12.
Wang, Keshan, Tianbo Xu, Hailong Ruan, et al.. (2019). LXRα promotes cell metastasis by regulating the NLRP3 inflammasome in renal cell carcinoma. Cell Death and Disease. 10(3). 159–159. 31 indexed citations
13.
Liu, Yuenan, Gong Cheng, Zhengshuai Song, et al.. (2019). RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma. International Journal of Oncology. 55(3). 645–656. 25 indexed citations
14.
Xu, Tianbo, Hailong Ruan, Zhengshuai Song, et al.. (2019). Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis. Biomedicine & Pharmacotherapy. 118. 109264–109264. 26 indexed citations
15.
Cheng, Yongbiao, Tianbo Xu, Sen Li, & Hailong Ruan. (2019). GPX1, a biomarker for the diagnosis and prognosis of kidney cancer, promotes the progression of kidney cancer. Aging. 11(24). 12165–12176. 49 indexed citations
16.
Ruan, Hailong, Lin Bao, Zhengshuai Song, et al.. (2019). High expression of TAZ serves as a novel prognostic biomarker and drives cancer progression in renal cancer. Experimental Cell Research. 376(2). 181–191. 9 indexed citations
17.
Song, Zhengshuai, Qi Cao, Hailong Ruan, et al.. (2018). RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma. Experimental Cell Research. 372(2). 118–128. 18 indexed citations
18.
Cao, Qi, Hailong Ruan, Keshan Wang, et al.. (2018). Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma. International Journal of Oncology. 53(1). 137–147. 64 indexed citations
19.
Wang, Keshan, Hailong Ruan, Tianbo Xu, et al.. (2018). Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer. OncoTargets and Therapy. Volume 11. 3167–3178. 33 indexed citations
20.
Wang, Keshan, Hailong Ruan, Zhengshuai Song, et al.. (2018). PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 36(7). 343.e9–343.e19. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhengshuai Song Breakdown of academic impact, for papers by Lin Bao Breakdown of academic impact, for papers by Ting Hong Breakdown of academic impact, for papers by Beatrice Dankworth Breakdown of academic impact, for papers by Wanyong Chen Breakdown of academic impact, for papers by Maria Quiles del Rey Breakdown of academic impact, for papers by Xiaozai Xie Breakdown of academic impact, for papers by Masaya Yonemori Breakdown of academic impact, for papers by Omar Moussa
Rankless by CCL
2026